华熙生物跌2.01%，成交额5361.81万元，主力资金净流出220.33万元

Core Viewpoint - Huaxi Bio's stock has experienced a decline of 8.13% year-to-date, with significant drops in recent trading periods, indicating potential challenges in the company's performance and market perception [1][2]. Company Overview - Huaxi Bio, established on January 3, 2000, and listed on November 6, 2019, is located in Jinan, Shandong Province. The company specializes in microbial fermentation and cross-linking technologies, developing bioactive materials that contribute to human health [1]. - The company's business model encompasses a full industry chain from raw materials to medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetics, food manufacturing companies, medical institutions, and end-users [1]. Financial Performance - For the period from January to September 2025, Huaxi Bio reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2]. - Since its A-share listing, Huaxi Bio has distributed a total of 1.138 billion yuan in dividends, with 528 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of November 20, 2025, Huaxi Bio had 30,100 shareholders, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per shareholder, an increase of 0.62% [2]. - The stock has seen significant net outflows of capital, with major funds selling more than they bought, indicating a cautious sentiment among investors [1]. Institutional Holdings - As of September 30, 2025, major institutional shareholders have reduced their holdings, with notable decreases in shares held by various ETFs, indicating a potential shift in investor confidence [3].